NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.36 +1.46 (+1.78%) GOLD FUTURES
2,335.90 -10.50 (-0.45%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,238.10 -144.93 (-0.27%)
REGENXBIO Inc. (RGNX)
After hours:
| Previous close | 15.64 |
| Open | 15.67 |
| Bid | 15.86 x 400 |
| Ask | 15.93 x 200 |
| Day's range | 15.52 - 16.28 |
| 52-week range | 11.83 - 28.80 |
| Volume | |
| Avg. volume | 746,629 |
| Market cap | 779.779M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.02 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.83 |
Simply Wall St.REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
PR NewswireREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Two-year data were published in The Lancet in a paper titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study." These positive study results informed the ongoing pi
- PR Newswire
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
